4-(1,4-dioxaspiro<4,5>dec-8-yl)-1-methylpiperazine | 155778-83-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(1,4-dioxaspiro<4,5>dec-8-yl)-1-methylpiperazine
• 英文别名: 1-methyl-4-(1,4-dioxaspiro[4.5]decan-8-yl)piperazine；1-(1,4-dioxaspiro[4.5]decan-8-yl)-4-methylpiperazine
• CAS: 155778-83-9
• 化学式: C₁₃H₂₄N₂O₂
• 分子量: 240.346
• InChiKey: AOKPRNQJOUPBTB-UHFFFAOYSA-N

物化性质

• 沸点：
  342.5±42.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.9
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4-(1,4-dioxaspiro<4,5>dec-8-yl)-1-methylpiperazine 在 盐酸 、 N-氯代丁二酰亚胺 、 对甲苯磺酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 109.0h， 生成 1,4-bis(6-chloro-4-(4-methylpiperazin-1-yl)cyclohex-1-en-1-yl)piperazine
  参考文献：
  名称：

  Functionalized chloroenamines in aminocyclopropane synthesis - XIV. Aminoannulated cyclopropanes - rigid building blocks for oligoamines

  摘要：

  Sterically pure meander oligoamines 5 possessing bicyclo[3.1.0]hexyl moieties as rigid building blocks were synthesized from monoketal 9 via di(chloroenamine) 14, bicyclic diketones 16 and subsequent reductive amination of 16. Use of the same reactions and change of the sequence of the steps led to hexamine 6a, a diastereomer of 5a. Hexamine 7a, a third diastereomer of 5a, was obtained with definite stereochemistry by a multistep approach starting from monoketal 9, too. X-Ray analysis of hexamine 5a, determination of basicity and studies of conformation and of molecular flexibility gave an insight in structural properties of the new type of meander oligoamines 5.

  DOI：

  10.1016/s0040-4020(01)80789-4
• 作为产物：
  描述：

  N-甲基哌嗪 、 1,4-环己二酮单乙二醇缩酮 在 三乙酰氧基硼氢化钠 、 溶剂黄146 、 sodium hydroxide 、 水 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 0.92h， 以99.1%的产率得到4-(1,4-dioxaspiro<4,5>dec-8-yl)-1-methylpiperazine
  参考文献：
  名称：

  WO2008/95944

  摘要：

  公开号：

文献信息

• USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE
  申请人：GRACZYK Piotr Pawel

  公开号：US20100069358A1

  公开（公告）日：2010-03-18

  The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.

  本发明提供了一种化合物(I)或其药学上可接受的盐，用于抑制c-Jun N末端激酶（JNK）活性，特别是用于治疗神经退行性疾病、炎症性疾病和/或自身免疫性疾病。本发明还提供了制备该化合物(I)或其药学上可接受的盐的方法和含有它们的组合物。
• 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE
  申请人：GRACZYK Piotr Pawel

  公开号：US20100069354A1

  公开（公告）日：2010-03-18

  The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.

  本发明提供了公式（I）的化合物；或其药学上可接受的盐，使用公式（I）的化合物或其药学上可接受的盐来抑制c-Jun N末端激酶（JNK）活性，并用于医药学，特别是用于治疗神经退行性疾病、炎症性疾病和/或自身免疫性疾病。本发明还提供了制备所述公式（I）的化合物或其药学上可接受的盐的方法和含有它们的组合物。
• Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US07951802B2

  公开（公告）日：2011-05-31

  The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.

  本发明提供了一种化合物(I)的公式；或其药学上可接受的盐，用于抑制c-Jun N末端激酶(JNK)活性，特别是用于治疗神经退行性疾病、炎症性疾病和/或自身免疫性疾病。本发明还提供了制备化合物(I)或其药学上可接受的盐的方法和含有它们的组合物。
• 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US08178552B2

  公开（公告）日：2012-05-15

  The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.

  本发明提供化合物(I)的公式；或其药学上可接受的盐，化合物(I)或其药学上可接受的盐在抑制c-Jun N-末端激酶（JNK）活性方面的用途，以及在医学上特别是治疗神经退行性疾病、炎症性疾病和/或自身免疫性疾病方面的用途。本发明还提供了制备上述化合物(I)或其药学上可接受的盐的方法和含有它们的组合物。
• WO2008/95944
  申请人：——

  公开号：——

  公开（公告）日：——